Research Paper Volume 13, Issue 3 pp 4258—4273
Cross-platform genomic identification and clinical validation of breast cancer diagnostic biomarkers
Figure 4. Clinical validation of hsa-miR-423-5p as an early diagnostic biomarker. (A) Heatmap for the differential expression of miRNA in plasma. Red labels indicate high expression and black labels indicate low expression. (B) A large cohort of breast cancer patients enrolled in serum hsa-miR-423-5p quantification, and the relative expression of hsa-miR-423-5p in breast cancer patients was significantly higher compared to that in controls (p<0.05). (C) A 1.5-fold increase in expression of hsa-miR-423-5p in the exosome of breast cancer patients was found. (D) The sensitivity and specificity analysis of hsa-miR-423-5p included analysis by the web tool easyROC (http://www.biosoft.hacettepe.edu.tr/easyROC).